Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIEOP-BFM ALL 2025 for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01Phase 3Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Disease-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2025-522190-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522190-11-01.